参考文献/References:
[1] 周薪, 府伟灵. 骨代谢异常的生物化学诊断//郑铁生, 主编. 临床生物化学与检验[M]. 第4版. 北京:人民卫生出版社.2008:296.
[2] Pallan S,Rahman MO,Khan AA.Diagnosis and management of primary hyperparathyroidism[J].BMJ, 2012,344:e10l 3.DOI: 10.1136/bmj.e1013.
[3] 金洋, 王颖, 金翠萍, 等. 老年高钙危象猝死1例报告[J]. 吉林医学,2014,35(1):223-224. DOI:10.3969/j.issn.1004-0412.2014.01.135.
[4] 邢小平, 孔晶, 王鸥. 高钙危象的诊治[J]. 临床内科杂志,2012, 29(9):590-592. DOI:10.3969/j.issn.1001-9057.2012.09.004.
[5] 谷伟军. 内分泌相关高钙血症的临床对策[J]. 药品评价,2014,11(1):12-16. DOI:10.3969/j.issn.1672-2809.2014.01.006.
[6] Ming SH, Sun TY. Clinical analysis of bisphosphonates treatment on bone metastases and hypercalcemia of malignancy in advanced solid tumor[J]. Chin J Cancer Res,2007,19(4):291-294.DOI: 10.1007/S11670-007-0291-2.
[7] Tanvetyanon T, Stiff PJ. Manngement of the adverse effects associated with intravenous bisphosphonates[J]. Ann Oncol, 2006,17(6):897-907. DOI:10.1093/annonc/mdj105.
[8] Papapetrou PD. Bisphosphonate associated adverse events[J]. Hormones(Athens), 2009,8(2):96-110.DOI:10.14310/horm.2002.1226.